We continue working to develop and obtain the Food and Drug Administration (FDA) authorization to market potentially reduced risk tobacco products and provide truthful and accurate communications about them to adult tobacco consumers.

In support of this work we regularly engage with the scientific, public health, and regulatory communities through face-to-face meetings, regulatory filings, publishing in scientific journals and participating at scientific conferences where we present our research. We listen to and welcome feedback on our work.

Reach Out

We are always interested in hearing from other scientists and stakeholders. If you have questions, would like to provide feedback on our work, or learn more about our research and our approach to harm reduction, contact us today.

Paige Magness Photo

Paige Magness

Senior Vice President, Regulatory Affairs

"For decades we have been committed to offering adult smokers better alternatives and ensuring a regulatory framework to determine if those products offer lower risk and how to appropriately communicate about them. We’re fully engaged in the science, policy and regulatory dialogue necessary to innovate and deliver acceptable alternatives adult smokers need and want."

Altria Scientists at the 60th Society of Toxicology (SOT) Virtual Conference – March 12-26, 2021

This year at the 60th Society of Toxicology Annual Conference and TOXEXPO our Pre-Clinical team shared 10 posters.

Altria Scientists at the 27th Society for Research on Nicotine and Tobacco (SRNT) Virtual Conference – February 24-27, 2021

On an annual basis SRNT offers an opportunity for diverse stakeholders to come together to share tobacco product research. This year our scientists participated in the 27th SRNT virtual conference showcasing 16 posters.

Recent Publication

Estimating the Population Health Impact of Recently Introduced Modified Risk Tobacco Products: A Comparison of Different Approaches.

Recent Publication

A 6-month Systems Toxicology Inhalation Study in ApoE -/- Mice Demonstrates Reduced Cardiovascular Effects of E-vapor Aerosols Compared With Cigarette Smoke.